MAP2K1 K57T

CI-VAR-00002146Explore in graph →CIViC 824

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm2
BRAF V600E AND MAP2K1 K57T	Cetuximab + Irinotecan + VemurafenibCombination	Predictive	C	Supports Resistance	2	submitted	EID1904 Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. Three patient… (full text at CIViC) PMID 27729313 · Hong et al., 2016 · Open in CIViC	civic
MAP2K1 K57T	Cetuximab	Predictive	C	Supports Resistance	3	submitted	EID2971 In a molecular case report, a MEK1 K57T mutation was found causing acquired resistancer to cetuximab. PMID 26644315 · Russo et al., 2016 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.